The RTZ provides young technology companies in their early stages with office and laboratory space, fully equipped seminar and meeting rooms, business support services, and access to an extensive network. As an incubator, it helps founders bring their ideas to life and lays the foundation for sustainable growth. Currently, around 40 companies form a vibrant community that thrives on collaboration and exchange.
Together with the BioCampus Cologne, RTZ forms part of Cologne’s high-tech hubs, home to more than 70 knowledge-based companies. These hubs offer start-ups, scale-ups, and corporates in the fields of deep tech, high tech, and STEM the ideal environment to transform ideas into successful business models. Tailored infrastructure – from offices and workshops to laboratories and event spaces – provides the framework for a lively, connected community.
myotwin extends its sincere thanks to the RTZ team for the warm welcome and looks forward to becoming part of this strong entrepreneurial community. With its new location, the company not only gains additional infrastructure but also an environment that actively fosters collaboration and innovation.
About myotwin
myotwin is a biotech company specializing in human–relevant, preclinical testing systems for the development of cardiovascular drugs. With its proprietary myoScreen platform, myotwin enables the simultaneous measurement of contraction force, tissue stiffness, calcium dynamics, and electrical activity—directly on human heart tissue.
As a next step, myotwin is developing myoAI, a digital twin of the heart muscle that uses artificial intelligence to predict the efficacy and toxicity of drugs. This is giving rise to a new generation of precise, data-driven drug development.
The Germany-based company works closely with research institutions, industry partners, and investors to advance innovative therapies for cardiovascular diseases more quickly and in a more targeted manner. For more information, visit www.myotwin.com.
Forward–looking statements
This communication may contain forward–looking statements based on current assumptions and forecasts made by myotwin’s management. Various known and unknown risks, uncertainties, and other factors could cause the actual results, financial position, development, or performance of the company to differ materially from the estimates given here. These factors include those described in myotwin’s public reports, which are available on the myotwin website at www.myotwin.com. The company assumes no obligation to update such forward-looking statements or to adapt them to future events or developments.
